Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 6, 2012, Pages 304-315

  Nagasaka, Yasuhisa ^a   Oda, Kazuo ^a   Iwatsubo, Takafumi ^a   Kawamura, Akio ^a   Usui, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

aripiprazole; BCRP; inhibition; MDR1; MRP4

Indexed keywords

ARIPIPRAZOLE; BREAST CANCER RESISTANCE PROTEIN; DEHYDROARIPIPRAZOLE; DIGOXIN; DRUG METABOLITE; ESTRADIOL; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 4; OLANZAPINE; PALIPERIDONE; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CELL MEMBRANE TRANSPORT; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFECT; DRUG POTENCY; DRUG TRANSPORT; IC 50; INTESTINE; INTESTINE ABSORPTION; MEMBRANE VESICLE; NONHUMAN; PROTEIN EXPRESSION; STEADY STATE; TRANSCYTOSIS;

ANIMALS; ANTIPSYCHOTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOTRANSFORMATION; BLOOD-BRAIN BARRIER; DIGOXIN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; INTESTINES; MADIN DARBY CANINE KIDNEY CELLS; MODELS, BIOLOGICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PERMEABILITY; PIPERAZINES; QUINOLONES; TRANSFECTION;

EID: 84866252879     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1801     Document Type: Article

References (39)

1. The International Transporter Consortium. Membrane transporters in drug development. Nature Rev Drug Discov 2010; 9: 215-236.
2. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling Recommendations draft guidance. US FDA website [online] 2012.
3. Choo EF, Leake B, Wandel C, et al,. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28: 655-660. (Pubitemid 30390404)
4. Ozvegy C, Litman T, Szakács G, et al,. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001; 285: 111-117. (Pubitemid 32912517)
5. Gupta A, Zhang Y, Unadkat JD, Mao Q,. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2004; 310: 334-341. (Pubitemid 38812728)
6. Ozvegy-Laczka C, Hegedus T, Várady G, et al,. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65: 1485-1495. (Pubitemid 38668306)
7. Prime-Chapman HM, Fearn RA, Cooper AE, Moore V, Hirst BH,. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 2004; 311: 476-484. (Pubitemid 39391531)
8. Leggas M, Adachi M, Scheffer GL, et al,. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004; 24: 7612-7621. (Pubitemid 39121487)
9. Ose A, Ito M, Kusuhara H, et al,. Limited brain distribution of [3R,4R,5 S]-4- acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 2009; 37: 315-321.
10. Lublin H, Eberhard J, Levander S,. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005; 20: 183-198. (Pubitemid 40896373)
11. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc. AbilifyTM (aripiprazole) tablets prescribing information [online]. Available from URL: http://www.abilify.com [Accessed 23 February 2012 ]
12. El Ela AA, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P,. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 2004; 56: 967-975. (Pubitemid 39140051)
13. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL,. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006; 187: 415-423. (Pubitemid 44200513)
14. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL,. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology 2007; 32: 757-764. (Pubitemid 46426181)
15. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, Yuan HJ, Devane CL,. Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic Clin Pharmacol Toxicol 2008; 103: 336-341.
16. Broccatelli F, Carosati E, Neri A, et al,. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem 2011; 54: 1740-1751.
17. Gao J, Murase O, Schowen RL, Aubé J, Borchardt RT,. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res 2001; 18: 171-176. (Pubitemid 32592596)
18. Citrome L, Macher JP, Salazar DE, Mallikaarjun S, Boulton DW,. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol 2007; 27: 279-283.
19. Heykants J, Huang ML, Mannens G, et al,. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55 (Suppl): 13-17. (Pubitemid 24179364)
20. Boom S, Talluri K, Janssens L, et al,. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009; 49: 1318-1330.
21. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM,. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177-193.
22. Aweeka F, Jayesekara D, Horton M, et al,. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 2000; 49 (Suppl. 1): 27S-33S. (Pubitemid 30151050)
23. Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y,. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 2009; 39: 430-443.
24. Urichuk L, Prior TI, Dursun S, Baker G,. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008; 9: 410-418. (Pubitemid 352025195)
25. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D,. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49 (Suppl 1): 35S-42S. (Pubitemid 30151051)
26. Feng B, Mills JB, Davidson RE, et al,. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 2008; 36: 268-275. (Pubitemid 351185738)
27. Wang JS, Zhu HJ, Donovan JL, et al,. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr Res 2009; 110: 90-94.
28. Kirschbaum KM, Uhr M, Holthoewer D, et al,. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010; 59: 474-479.
29. Eyal S, Hsiao P, Unadkat JD,. Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 2009; 123: 80-104.
30. Bundgaard C, Jensen CJ, Garmer M,. Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice. Drug Metab Dispos 2012; 40: 461-466.
31. Pedersen KE, Christiansen BD, Klitgaard NA, Nielsen-Kudsk F,. Effect of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 1983; 24: 41-47. (Pubitemid 13181784)
32. Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J,. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther 1988; 43: 668-672.
33. Baris N, Kalkan S, Güneri S, Bozdemir V, Guven H,. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? Eur J Clin Pharmacol 2006; 62: 535-538.
34. Fenner KS, Troutman MD, Kempshall S, et al,. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009; 85: 173-181.
35. Fremstad D, Nilsen OG, Storstein L, Amlie J, Jacobsen S,. Pharmacokinetics of quinidine related to plasma protein binding in man. Eur J Clin Pharmacol 1979; 15: 187-192. (Pubitemid 9235734)
36. Keefe DL, Yee YG, Kates RE,. Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther 1981; 29: 21-26. (Pubitemid 11156044)
37. Lentz KA, Quitko M, Morgan DG, Grace JE Jr, Gleason C, Marathe PH,. Development and validation of a preclinical food effect model. J Pharm Sci 2007; 96: 459-472. (Pubitemid 46363575)
38. 50 criteria in the P-gp decision tree. J Clin Pharmacol 2012 Feb 7. [Epub ahead of print].
39. Singh B, Khurana L, Bandyopadhyay S, Kapil R, Katare OO,. Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential. Drug Deliv 2011; 18: 599-612.